Sanofi (SAN) Ordinary Euro 2
- Add to watchlist
- This stock can be held in a
Share news, reports & tips
-
Sanofi to sell 50% stake in Opella to CD&R
21 October 2024 12:55
(Sharecast News) - Sanofi said on Monday that it has agreed to sell a 50% stake in its consumer healthcare business, Opella, to US private equity firm Clayton, Dubilier & Rice in a €16bn deal.
-
Sanofi in talks to sell consumer healthcare stake to US private equity firm
11 October 2024 08:08
(Sharecast News) - French pharma giant Sanofi has announced it is in discussions with US private equity firm Clayton, Dubilier & Rice regarding the potential sale of half of its consumer healthcare...
-
Novavax signs $1.2bn Covid-19 licensing deal with Sanofi, shares rocket
10 May 2024 11:47
(Sharecast News) - Shares of US biotech firm Novavax rocketed on Friday after it signed a $1.2bn licensing agreement with French pharmaceutical group Sanofi to commercialise its Covid-19 vaccine from next year.
-
Sanofi shares tank on consumer spin-off plans, Q3 profit miss
27 October 2023 08:43
(Sharecast News) - Sanofi has announced plans to split its consumer-healthcare and pharmaceutical business, as it missed profit expectations for the third quarter, causing shares to drop over 15% on Friday.
-
GSK settles California Zantac lawsuit
11 October 2023 11:51
(Sharecast News) - GSK has agreed to settle another lawsuit concerning its discontinued heartburn treatment Zantac, the drugs giant confirmed on Wednesday.
-
AstraZeneca, Sanofi infant respiratory treatment gets US approval
18 July 2023 08:10
(Sharecast News) - AstraZeneca and Sanofi's Beyfortus drug has been approved in the US for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and...
-
Sanofi to buy Provention Bio in $2.9bn deal
13 March 2023 09:59
(Sharecast News) - French pharmaceutical company Sanofi said on Monday that it has agreed to buy US biopharmaceutical group Provention Bio for $2.9bn in cash.
-
AstraZeneca, Sanofi respiratory drug gets EU marketing go-ahead
16 September 2022 07:02
(Sharecast News) - AstraZeneca and Sanofi said their Beyfortus drug for the prevention of lower respiratory tract disease in newborns and infants has been recommended for marketing authorisation in the...
-
GSK to 'vigorously defend' Zantac claims; Haleon says not a party to claims
12 August 2022 07:26
(Sharecast News) - GlaxoSmithKline said on Friday that it would "vigorously defend" all claims related to its discontinued heartburn drug Zantac.
-
GSK, Haleon, Sanofi slump amid Zantac litigation woes
11 August 2022 12:35
(Sharecast News) - Shares in GlaxoSmithKline, Haleon and Sanofi tumbled on Thursday amid concerns about legal proceedings related to Glaxo's former blockbuster heartburn drug Zantac.
-
GSK and Sanofi seek approval for Covid-19 jab
23 February 2022 11:23
(Sharecast News) - GlaxoSmithKline and Sanofi are to seek regulatory approval for their Covid-19 vaccine candidate following successful efficacy trials.
-
GSK-Sanofi Covid jab shows 'strong' immune response
15 December 2021 07:05
(Sharecast News) - A Covid-19 vaccine booster being developed by GlaxoSmithKline and Sanofi has been shown to be effective across all age groups tested, according to data released by the UK drugs firm on...
Company announcements Announcements
No company announcements about Sanofi Ordinary Euro 2 were found.
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2024. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.